Wells Fargo & Company »

Rapport Therapeutics shares owned by Wells Fargo & Company

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Wells Fargo & Company from 13F filings

Historical chart of Wells Fargo & Company investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Wells Fargo & Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Wells Fargo & Company

Quarter filed Position value Share count Share price at filing
2024-09-30 $71k 3.5k 20.48

More positions owned by Wells Fargo & Company

Microsoft Corporation (MSFT)
Apple Put Option (AAPL)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Ishares Tr Russell 2000 Etf (IWM)
Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Core S&p Ttl Stk (ITOT)
NVIDIA Corporation (NVDA)
Vanguard Index Fds Mid Cap Etf (VO)
Amazon (AMZN)
JPMorgan Chase & Co. Put Option (JPM)
Ishares Tr Core Us Aggbd Et (AGG)
Ishares Tr Core Msci Eafe (IEFA)
UnitedHealth (UNH)
Broadcom (AVGO)

View all positions for Wells Fargo & Company

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics